The Firm recently represented the underwriters, led by Barclays Bank PLC, BofA Securities Europe SA and Citigroup Global Markets Europe AG, in connection with the public offering by American Medical Systems Europe B.V. of €3 billion of debt securities, fully and unconditionally guaranteed by Boston Scientific Corporation (“Boston Scientific”), consisting of €1 billion of 0.75% Senior Notes due 2025, €750 million of 1.375% Senior Notes due 2028, €750 million of 1.625% Senior Notes due 2031 and €500 million of 1.875% Senior Notes due 2034. Boston Scientific used the net proceeds from the offering, together with short-term borrowings and cash on hand, to fund a related cash tender offer and to pay accrued and unpaid interest, premiums, fees and expenses in connection with the tender offer.
In addition, the Firm represented the dealer managers, led by Barclays Capital Inc., BofA Securities, Inc. and Citigroup Global Markets Inc., in connection with the related cash tender offer for $2.85 billion aggregate principal amount of Boston Scientific’s outstanding 3.375% Senior Notes due 2022, 4.125% Senior Notes due 2023, 4.7% Senior Notes due 2049, 4.55% Senior Notes due 2039, 4% Senior Notes due 2029, 4% Senior Notes due 2028, 3.85% Senior Notes due 2025, 3.75% Senior Notes due 2026 and 3.45% Senior Notes due 2024.
Boston Scientific, as a global medical technology leader for over 40 years, advances science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.
The Simpson Thacher team for the transaction included Roxane Reardon, Patrick Baron, Carlie Marks and Daniel Westen (Capital Markets); Jonathan Cantor and Edward Grais (Tax); Lori Lesser and Alysha Sekhon (Intellectual Property); Vanessa Burrows (Healthcare); Michael Isby (Environmental); Jeanne Annarumma and Brian Chung (ECEB); and Jennie Getsin (FINRA/Blue Sky).